Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL             |        |  |  |  |  |  |  |  |  |  |
|--------------------------|--------|--|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0287    |        |  |  |  |  |  |  |  |  |  |
| Estimated average burden |        |  |  |  |  |  |  |  |  |  |
| hours per response       | e: 0.5 |  |  |  |  |  |  |  |  |  |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Hesslein Robert W.   |  |       |   |          |   | 2. Issuer Name and Ticker or Trading Symbol Voyager Therapeutics, Inc. [ VYGR ] |  |     |  |          |                    |  |  | (Ched        | k all app   | ,   | ng Pei | rson(s) to Is<br>10% O<br>Other ( | wner  |
|--|--|-------|---|----------|---|---|--|-----|--|----------|--------------------|--|--|--------------|---|---|--------|-----------------------------------|-------|
| (Last) (First) (Middle) C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET   |  |       |   |          |   | 3. Date of Earliest Transaction (Month/Day/Year) 04/05/2021                     |  |     |  |          |                    |  |  | X            | belov   | below) Senior VP & 0  |        | below)                            | ·     |
| (Street) CAMBR (City)  | IDGE M   | A 0   | 2139<br>Zip)                            |          | 4. If A   | 4. If Amendment, Date of Original Filed (Month/Day/Year)                        |  |     |  |          |                    |  | 6. Ind<br>Line)<br>X   | Form<br>Form | idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person |   |        |                                   |       |
|  |  | Table | I - No                                  | n-Deriva | tive S  | Secu  | rities   | Acq | uired,   | Dis      | posed of           | , or E                                       | 3enef  | iciall       | y Own   | ed  |        |                                   |       |
| 1. Title of Security (Instr. 3)  2. Transact Date (Month/Day   |  |       |   |          | Execution Date,   |   |  |     | es Acquired (A<br>Of (D) (Instr. 3,  |          |                    | Securit<br>Benefic                           | eficially<br>ned Following   |              | wnership<br>n: Direct<br>or Indirect<br>nstr. 4)  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |        |                                   |       |
|  |  |       |   |          |   |   |  |     |  | v        | Amount             | (A)<br>(D)                                   | or P   | rice         | Transa  | saction(s)<br>r. 3 and 4)   |        |                                   | (5 4) |
| Common Stock 04/05/2   |  |       |   |          | 2021  |   |  | S   |  | 3,292(1) |                    | A 5  | \$4.95   | 110,056      |   |   | D      |                                   |       |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |  |       |   |          |   |   |  |     |  |          |                    |  |  |              |   |   |        |                                   |       |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any |       | 4.<br>Transaction<br>Code (Instr.<br>8) |          | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3, 4<br>and 5) |   | 6. Date Exercisable and Expiration Date (Month/Day/Year) |     | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Ins<br>3 and 4) |          | De Se (In          | Price of<br>erivative<br>ecurity<br>estr. 5) | 9. Number<br>derivative<br>Securities<br>Beneficiall<br>Owned<br>Following<br>Reported<br>Transactio<br>(Instr. 4) | у            | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4)  | 11. Nature<br>of Indirect<br>Beneficia<br>Ownership<br>(Instr. 4) |        |                                   |       |
|  |  |       |   |          | Code  | v   | (A)  | (D) | Date<br>Exercis  | able     | Expiration<br>Date | Title  | of<br>Share  | s            |   |   |        |                                   |       |

## **Explanation of Responses:**

1. Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

/s/ Allison Dorval, as

Attorney-in-Fact for Robert

04/07/2021

W. Hesslein

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.